Albert David Limited

ALBERTDAVD

INE155C01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:43:25 07/06/2024 pm IST			5-day change	1st Jan Change
1,182 ^INR	+9.35%		+6.08%	+21.12%

13/05	Albert David Limited Announces Executive Changes, Effective June 1, 2024	CI
13/05	Albert David Limited Recommends Final Dividend for the Year Ended on March 31, 2024	CI

Albert David Limited Announces Executive Change

November 11, 2020 at 06:13 pm IST

Albert David Limited announced Mr. Subhash Chandra Shah shall retire as Key Managerial Personnel with effect from close of business hours of 30 November, 2020. Mr. Ranadeep Bhattacharya will be appointed as Key Managerial Personnel of the Company with effect from 1st December, 2020.

Latest news about Albert David Limited

Albert David Limited Announces Executive Changes, Effective June 1, 2024	13/05	CI
Albert David Limited Recommends Final Dividend for the Year Ended on March 31, 2024	13/05	CI
Albert David Limited Reports Earnings Results for the Full Year Ended March 31, 2024	13/05	CI
Albert David Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	13/05	CI
Albert David Limited Announces Resignation of Abhishek Seth as Company Secretary & Compliance Officer, Effective May 31, 2024	04/05	CI
Albert David Limited Announces Board Retirement	01/04	CI
Albert David Limited Announces Management Changes	14/03	CI
Albert David Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	05/02	CI
Albert David Limited Announces Resignation of A. B. Chakrabartty as Company Secretary and Compliance Officer Cum Legal Head of the Company	22/11	CI
Albert David Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Albert David to Invest INR6 Million in Solar Power Company	08/23/08	MT
Sunsure Solarpark Five Private Limited announced that it expects to receive INR 6.125 million in funding from Albert David Limited	08/23/08	CI
Albert David Limited Approves Dividend for the Financial Year Ended March 31, 2023	10/23/10	CI
Albert David Limited Announces Board Changes	10/23/10	CI
Albert David Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/23/10	CI
Albert David Limited Recommends Dividend for the Financial Year 2022-2023	19/23/19	CI
Albert David Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	19/23/19	CI
CARE Upgrades Rating on Albert David's Long-term Bank Financing; Outlook Stable	30/23/30	MT
Albert David Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Albert David Names New CEO	06/23/06	MT
Albert David Limited Appoints Mr. A B Chakrabartty as the Company Secretary & Compliance Officer Cum Legal Head of the Company	04/23/04	CI
Albert David Limited Appoints Mr. Umesh Kunte as the Chief Executive Officer, Effective on February 06, 2023	04/23/04	CI
Albert David Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	12/22/12	CI
Albert David Limited Announces Reconstitution of Committees of the Board of Directors	13/22/13	CI
Albert David CEO Resigns	09/22/09	MT

Chart Albert David Limited

Duration

Period

More charts

Company Profile

Albert David Limited is engaged in manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. The Company offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. It has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.

Sector

Pharmaceuticals

Calendar

02/08/2024 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ALBERT DAVID LIMITED	+21.12%	8.08Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.64%	4.33TCr
OTSUKA HOLDINGS CO., LTD.	+21.25%	2.22TCr
SANDOZ GROUP AG	+18.92%	1.54TCr
CIPLA LIMITED	+20.14%	1.45TCr
ZYDUS LIFESCIENCES LIMITED	+53.19%	1.27TCr
THE MEDICINES COMPANY	-0.05%	678.76Cr
ONO PHARMACEUTICAL CO., LTD.	-11.11%	670.81Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+14.68%	549.79Cr